Published Date: April 27, 2023

Full Text Article

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML

Authors: D Nixdorf, M Sponheimer, D Berghammer, F Engert, U Bader, N Philipp, M Kazerani, T Straub, L Rohrbacher, L Wange, S Dapa, D Atar, C M Seitz, K Brandstetter, A Linder, M von Bergwelt, H Leonhardt, J Mittelstaet, A Kaiser, V B├╝cklein, M Subklewe

Although the landscape for treating acute myeloid leukemia (AML) patients has changed substantially in recent years, the majority of patients will eventually relapse and succumb to their disease. Allogeneic stem cell transplantation provides the best anti-AML treatment strategy, but is only suitable in a minority of patients. In contrast to B-cell neoplasias, chimeric antigen receptor (CAR) T-cell therapy in AML has encountered challenges in target antigen heterogeneity, safety, and T-cell...

PMID: 37106163DOI: 10.1038/s41375-023-01905-0PMC: PMC10244166